Mary Lou Affronti

1.6k total citations
58 papers, 1.1k citations indexed

About

Mary Lou Affronti is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Lou Affronti has authored 58 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 18 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Lou Affronti's work include Glioma Diagnosis and Treatment (24 papers), Nausea and vomiting management (12 papers) and Brain Metastases and Treatment (9 papers). Mary Lou Affronti is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), Nausea and vomiting management (12 papers) and Brain Metastases and Treatment (9 papers). Mary Lou Affronti collaborates with scholars based in United States, France and United Kingdom. Mary Lou Affronti's co-authors include Henry S. Friedman, James E. Herndon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich, David A. Reardon, Maureen Ross, Darell D. Bigner and Allan H. Friedman and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Mary Lou Affronti

51 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Lou Affronti United States	17	430	325	318	181	160	58	1.1k
Eric Lipp United States	19	488 1.1×	186 0.6×	264 0.8×	152 0.8×	246 1.5×	85	940
Yazmín Odia United States	20	569 1.3×	217 0.7×	205 0.6×	195 1.1×	446 2.8×	89	1.2k
Jacob Mandel United States	15	368 0.9×	251 0.8×	240 0.8×	123 0.7×	116 0.7×	54	860
J. Biau France	20	283 0.7×	471 1.4×	440 1.4×	147 0.8×	340 2.1×	113	1.3k
Ashley Sumrall United States	15	500 1.2×	387 1.2×	255 0.8×	76 0.4×	79 0.5×	55	934
Thankamma Ajithkumar United Kingdom	20	353 0.8×	395 1.2×	300 0.9×	64 0.4×	133 0.8×	65	1.2k
Rakesh Jalali India	20	543 1.3×	314 1.0×	143 0.4×	113 0.6×	100 0.6×	94	1.0k
Armin Muigg Austria	11	315 0.7×	171 0.5×	205 0.6×	92 0.5×	220 1.4×	23	883
Sang-Hue Yen Taiwan	17	253 0.6×	153 0.5×	144 0.5×	132 0.7×	308 1.9×	42	886
Curtis Miyamoto United States	24	241 0.6×	376 1.2×	339 1.1×	70 0.4×	171 1.1×	63	1.4k

Countries citing papers authored by Mary Lou Affronti

Since Specialization

Citations

This map shows the geographic impact of Mary Lou Affronti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Lou Affronti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Lou Affronti more than expected).

Fields of papers citing papers by Mary Lou Affronti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Lou Affronti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Lou Affronti. The network helps show where Mary Lou Affronti may publish in the future.

Co-authorship network of co-authors of Mary Lou Affronti

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Lou Affronti. A scholar is included among the top collaborators of Mary Lou Affronti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Lou Affronti. Mary Lou Affronti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Herndon, James E., et al.. (2024). Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample. American Journal of Hospice and Palliative Medicine®. 42(9). 862–868.

Affronti, Mary Lou, Jiyeon Lee, Alex Molassiotis, et al.. (2024). MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients. Supportive Care in Cancer. 32(6). 335–335. 2 indexed citations

Affronti, Mary Lou, et al.. (2024). Financial toxicity of oral chemotherapy in patients with primary brain tumors. Neuro-Oncology Practice. 12(1). 153–159.

Silva, Susan G., et al.. (2023). Nurse practitioner satisfaction with in-person versus telehealth chronic care delivery. Journal of the American Association of Nurse Practitioners. 36(3). 160–170.

Molassiotis, Alex, Mary Lou Affronti, Mapi Fleury, et al.. (2023). 2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Supportive Care in Cancer. 32(1). 30–30. 6 indexed citations

Randazzo, Dina, Frances McSherry, James E. Herndon, et al.. (2021). Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. Neuro-Oncology Practice. 8(3). 299–309. 15 indexed citations

Randazzo, Dina, Frances McSherry, James E. Herndon, et al.. (2019). Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. Complementary Therapies in Clinical Practice. 36. 43–48. 8 indexed citations

Affronti, Mary Lou, et al.. (2019). Improving Attitudes and Perceptions About End-of-Life Nursing on a Hospital-Based Palliative Care Unit. Journal of Hospice and Palliative Nursing. 21(4). 272–279. 13 indexed citations

Peters, Katherine B., John P. Kirkpatrick, Ines Batinić‐Haberle, et al.. (2018). ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. Neuro-Oncology. 20(suppl_6). vi17–vi17. 3 indexed citations

10.

Clark-Snow, Rebecca, Mary Lou Affronti, & Cynthia N. Rittenberg. (2017). Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Supportive Care in Cancer. 26(2). 557–564. 51 indexed citations

11.

Rittenberg, Cynthia N., Rebecca Clark-Snow, & Mary Lou Affronti. (2016). Impact of chemotherapy-induced nausea and vomiting (CINV) on emergency department (ED) visits and disruption of chemotherapy: results of a survey of oncology nurses. Annals of Oncology. 27. vi500–vi500. 1 indexed citations

12.

Affronti, Mary Lou, Karen Allen, John P. Kirkpatrick, et al.. (2016). Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Supportive Care in Cancer. 24(10). 4365–4375. 8 indexed citations

13.

Randazzo, Dina, Frances McSherry, James E. Herndon, et al.. (2015). Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. Journal of Clinical Oncology. 33(15_suppl). 9553–9553. 2 indexed citations

14.

Rich, Jeremy N., Mary Lou Affronti, Jeannette M. Day, et al.. (2007). Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. Journal of Clinical Oncology. 25(18_suppl). 2070–2070. 7 indexed citations

15.

Bota, Daniela A., Annick Desjardins, Jennifer A. Quinn, Mary Lou Affronti, & Henry S. Friedman. (2007). Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.. PubMed. 3(5). 707–15. 81 indexed citations

16.

Vredenburgh, James J., David Coniglio, Maureen Ross, et al.. (2006). A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplantation. 37(11). 1009–1015. 27 indexed citations

17.

Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, et al.. (2004). Phase 1 trial of irinotecan plus BCNU in patients with progressive orrecurrent malignant glioma. Neuro-Oncology. 6(2). 145–153. 24 indexed citations

18.

Vandemark, Robert M., Elizabeth J. Shpall, & Mary Lou Affronti. (1992). Bone Metastases from Breast Cancer. Journal of Computer Assisted Tomography. 16(4). 608–614. 16 indexed citations

19.

Shpall, Elizabeth J., Roy B. Jones, Robert C. Bast, et al.. (1991). 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.. Journal of Clinical Oncology. 9(1). 85–93. 75 indexed citations

20.

Jones, Roy B., Elizabeth J. Shpall, Maureen Ross, et al.. (1990). High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemotherapy and Pharmacology. 26(2). 155–156. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact